Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represents HealthCap and Wilson Therapeutics AB in private placement
Mandate

Vinge represents HealthCap and Wilson Therapeutics AB in private placement

May 22, 2014

Wilson Therapeutics AB has completed a private placement of USD 40,000,000 (SEK 260,000,000) directed to the venture capital firms Abingworth LLP and MVM Life Science Partners LLP and the existing investor HealthCap.

Wilson Therapeutics AB is a life science company focused on the development of drugs for the treatment of Wilson’s Disease, a rare genetic disease that affects approximately 1 in 15,000 people worldwide. The private placement is conducted to finance further product development, clinical trials and commercialisation of the company’s products.

Vinge represented HealthCap and Wilson Therapeutics AB in the private placement and Vinge’s team consisted of partner Jesper Ottergren together with, among others, Kristian Ford and Karin Engström.

Related

Vinge has advised Ingka Investments on its largest forestland acquisition

 Ingka Investments, the investment arm of Ingka Group (the world’s largest IKEA retailer), has agreed to acquire approximately 153,000 hectares of land, mainly forestland, from Södra, Sweden’s largest forest owners’ association.
October 20, 2025

Vinge advises Procuritas on its acquisition of Parkman

 Vinge has advised Procuritas Capital Investors VII (“Procuritas”) in connection with the acquisition of Parkman i Sverige AB (“Parkman”), a growing Swedish tech-enabled parking operator that provides parking management solutions. As part of the transaction, Indigo Management AS becomes a minority owner of the company.
October 20, 2025

Vinge has advised Eleda in connection with the acquisition of Nordic Infrastructure Group AS (“Qben Rail”)

 Qben Infra AB and ININ Group AS, which is majority owned by Qben Infra AB, have entered into a share purchase agreement with Eleda through Eleda’s subsidiary Eleda Norge AS (“Eleda”), to divest the Qben Rail platform to Eleda for a total enterprise value of up to NOK 850 million, including an earn out of up to NOK 65 million. Completion of the transaction is subject to customary closing conditions, including approval from the Swedish Inspectorate of Strategic Products and the Norwegian Competition Authority.
October 17, 2025